IPierian gets back to drug discovery basics

As a startup, iPierian boasted some of the world's top experts on stem cells. The impeccable scientific pedigree, however, never translated into the kind of partnering deals the biotech was looking for. And the lack of deals triggered turmoil at the helm. Now new CEO Nancy Stagliano tells San Francisco Business Times writer Ron Leuty the company will return to its IPS cells roots, looking for new treatments for tough neurodegenerative diseases like Alzheimer's and spinal muscular atrophy. "We explored various avenues, including extensive partnering, and concluded that the best place is to put (the company's focus) on neurodegeneration and internal pipelines, with an emphasis on drug discovery," Stagliano tells the SFBT. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.